Biolase, Inc.
BIOL
BIOL was delisted on the 18th of June, 2024.
19 hedge funds and large institutions have $6.54M invested in Biolase, Inc. in 2019 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 4 closing their positions.
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
19% more funds holding
Funds holding: 16 → 19 (+3)
16% less capital invested
Capital invested by funds: $7.83M → $6.54M (-$1.29M)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
+$812K |
| 2 |
ACM
Archon Capital Management
Seattle,
Washington
|
+$628K |
| 3 |
WPC
White Pine Capital
Bloomington,
Minnesota
|
+$388K |
| 4 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$323K |
| 5 |
VF
Virtu Financial
New York
|
+$18.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TA
Teton Advisors
Rye,
New York
|
-$21K |
| 2 |
Bank of New York Mellon
New York
|
-$10K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$6.15K |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$3K |
| 5 |
Morgan Stanley
New York
|
-$1.54K |
BIOL Hedge Fund Activity: Q4 2019 in Review
19 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Biolase, Inc. (BIOL) for Q4 2019, worth a combined $6.54M — down 16% from $7.83M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new BIOL positions and 4 closed out — a net gain of 3 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Perkins Capital Management, opening a new position worth an estimated $812K. The largest seller was Teton Advisors, exiting entirely with an estimated $21K sold.
- 19 institutional investors held Biolase, Inc. (BIOL) as of Q4 2019, up from 16 in Q3 2019.
- Funds reported $6.54M of Biolase, Inc. stock for Q4 2019, down 16% quarter-over-quarter.
- 7 funds opened new Biolase, Inc. positions in Q4 2019 and 4 closed out, a net change of +3 holders.
- The largest Biolase, Inc. buyer in Q4 2019 was Perkins Capital Management, an estimated $812K added.
- The largest Biolase, Inc. seller in Q4 2019 was Teton Advisors, an estimated $21K sold.
Based on aggregated 13F filings for Q4 2019.